markers, thus enabling and designing possible therapies. We applied mass spectrometry to provide metabolic profiles of brain tissue and plasma over time following an excitotoxic lesion (intracerebral ibotenate) to the neonatal (postnatal day 5) mouse brain. We found no differences between the plasma from the control (PBS-injected) and excitotoxic (ibotenate-injected) groups over time (on postnatal days 8, 9, 10, and 30). In the brain, we found that variations in amino acids (arginine, glutamine, phenylananine, and proline) and glycerophospholipids were sustaining acute and delayed (tertiary) responses to injury. In particular, the effect of the excitotoxic lesion on the normal profile of development was linked to alterations in a fingerprint of glycerophospolipids Keywords Ibotenate · Stroke · Hypoxic-ischemic encephalopathy · Diffuse white matter injury · Metabolomics · Mass spectrometry · Metabonomics · Neonatal encephalopathy Abstract Excitotoxicity plays a key role during insults to the developing brain such as neonatal encephalopathy, stroke, and encephalopathy of prematurity. Such insults affect many thousands of infants each year. Excitotoxicity causes frank lesions due to cell death and gliosis and disturbs normal developmental process, leading to deficits in learning, memory, and social integration that persist into adulthood. Understanding the underlying processes of the acute effects of excitotoxicity and its persistence during brain maturation provides an opportunity to identify mechanistic or diagnostic bio- and amino acids. Specifically, we identified increases in the amino acids glutamine, proline, serine, threonine, tryptophan, valine, and the sphingolipid SM C26: 1, and decreases in the glycerophospholipids, i.e., the arachidonic acid-containing phosphatidylcholine (PC aa) C30: 2 and the PC aa C32: 3. This study demonstrates that metabolic profiling is a useful approach to identify acute and tertiary effects in an excitotoxic lesion model, and generating a short list of targets with future potential in the hunt for identification, stratification, and possibly therapy.
Introduction
Excitotoxicity plays a key role in insults to the developing brain such as neonatal encephalopathy [1, 2] , stroke [3, 4] , encephalopathy of prematurity [5, 6] , and traumatic brain injury [7] . Many thousands of infants suffer from these injuries every year in developed countries alone. Due to acute effects, such as cell death, and subsequent disturbances to normal development, these insults are a leading cause of deficits in learning, memory, and social integration that persist into adulthood [8] [9] [10] . During excitotoxicity, the excessive activation of glutamate receptors, particularly N-methyl-D-aspartate (NMDA) receptors, leads to vast calcium influx, leading to cellular membrane damage and the leakage of reactive oxygen species from mitochondria, inducing neural cell death and a subsequent loss of neurites and connectivity [11] [12] [13] . However, the indiscriminate targeting of NMDA receptors induces localized neuronal death and behavioral deficits in adulthood [14, 15] as well as massive and diffuse neuronal death in the developing brain [16, 17] ; this is due to their crucial developmental and homeostatic functions. Preventing excitotoxic injury without directly interfering with NMDA receptors is therefore an appealing therapeutic strategy. Furthermore, lesions associated with excitotoxicity causes persisting micro-and astrogliosis, and this and other persisting processes may also represent viable neurotherapeutic targets [18] . A relatively novel approach in the search for therapeutic targets is metabolic phenotyping. Metabolites represent the functional end points of gene and protein expression, and are also known as important modulators of cell signaling and cell survival. As such, metabolic phenotyping can be considered to encompass the overall physiologic status of an organism by capturing global biochemical events by assaying many hundreds of small molecules in cells, tissues, and organs. This approach has been applied for acute-injury profiling and, in the developing brain, it is well-known that hypoxia-ischemia induces major changes in metabolism. In 1984, Silverstein and Johnston [19] described the effects on monoamine metabolism in infants diagnosed with hypoxic-ischemic encephalopathy. This work was extended in an experimental setting in fetal monkeys subjected to perinatal hypoxic insult [20] , and changes in arachidonic acid metabolites was reported in 1989 in the fetal rabbit following brain hypoxia [21] . It took several decades until the importance of these metabolites was discovered [22] , and, recently, the effects (and altered levels) of endocannabinoids under ischemic and excitotoxic conditions became of interest [23, 24] . More recently, the use of fluid metabolic phenotyping has been applied to clinical samples following perinatal brain injury in order to determine biomarkers [25, 26] ; improving our knowledge of the injury-specific and temporal components of the metabolic profile will improve the interpretation of this research.
We undertook a comprehensive analysis of the metabolic phenotype to both confirm and expand our knowledge about the expected mode of action of excitotoxicity. We hoped to possibly pinpoint pathways, aside from those identified in nonmetabolic phenotyping approaches or nonpediatric based analyses, which could lead to the identification of new therapeutic targets [27] . Our hypothesis is that we that we could use screening for metabolic phenotypes and the associated multivariate biostatistical analysis to provide new information on the effects of injury on and between multiple metabolites over time.
We studied the well-validated and characterized excitotoxic lesion in a postnatal day 5 mouse model [28] [29] [30] . The lesion size following ibotenate injection is maximal after 24 h, and remains stable for at least the following 4 weeks [28, 29] . The initial injury involves the death of neurons and astrocytes across all cortical and subcortical layers, and the almost immediate infiltration of microglia [28] . Although microglial and astrocyte numbers within the lesion return to normal (although the phenotype is unknown), the injury to the periventricular white matter persists [28] . In this excitotoxic model, we characterized the metabolic fingerprint occurring within the lesion and plasma at 5 time points, from the acute phase into young adulthood. We found that the excitotoxic lesion caused a substantial change away from the profile observed in the control, i.e., the group injected with PBS only. We observed a handful of metabolites, related to amino acids and lipids, to be altered by the excitotoxic lesion.
Materials and Methods
Experimental protocols were approved by the Bichat and Robert Debré Hospital ethics committee (No. 2011-14/646-048) and all experiments adhered to the European Union Guidelines for the Care and Use of Animals. In vivo procedures were typically carried out between 10 a.m. and 1 p.m. (light phase 7 a.m. to 7 p.m. daily); all animals were monitored daily during experimentation. Each experimental unit corresponded to a single animal, with groups spread between and across litters. The mice were housed (Plexiglass cages 30 × 18 × 15 cm) together with their littermates and their dam from birth to P20, and were weaned into single-sex groups at P21. Cages were supplied with wood-chip bedding and shredded paper for nesting (Pharmaserv, France) and the mice had access to standard chow and water ad libitum.
Animals and Drugs
Male and female Swiss pups (Iffa Credo, L'Abresle, France) were used for in vivo experiments. The ibotenate was purchased from Sigma (St. Louis, MO, USA). It was diluted in 1× PBS containing 0.01% acetic acid.
Neonatal Excitotoxic Brain Lesions and Sample Collection
We induced excitotoxic brain lesions by injecting ibotenate into the developing mouse neopallial parenchyma on postnatal day 5 as previously described [2, 31, 32] . In brief, using a stereotactic frame, a 26-gauge syringe was inserted under the external surface of the scalp, 2 mm from the midline in the lateral medial plane and 3 mm from the junction between the sagittal and lamboid sutures in the rostrocaudal plane. A 1-μL bolus of ibotenate (5 ng/μL in 0.01% acetic acid in 1× PBS) was administered at a 2-μm depth (periventricular white matter placement), the needle was then withdrawn 1 μm (cortical placement) and a second 1-μL bolus was administered. The needle was held in place for 20 s following the injections. Animals were euthanized by decapitation at 24, 48, 72, and 120 h, or 25 days after the injury. Blood was collected at decapitation using capillary tubes and was separated from plasma via centrifugation. The brain region corresponding to the site of injection was dissected out, and the blood and plasma were stored at -80 ° C until further preparation (described below). Specifically, the area of the excitotoxic lesion was dissected by excising an area 2 × 2 mm of the whole depth of the cortex and underlying subcortical white matter from the injection site at each age. Although the necessity to take the entire lesion area for analysis precluded analysis of lesion size, animals performed in parallel for a separate study had the expected lesion size for this highly reproducible model [28, [33] [34] [35] . Each treatment group comprised 7-10 animals.
Sample Preparation
Frozen brain samples were weighted into 2-mL Precellys tubes (Peqlab Biotechnologie GmbH, Erlangen, Germany) equipped with ceramic beads. Homogenates were prepared by adding ethanol/10 m M phosphate buffer (85/15) solvent mixtures to the tissue sample in a ratio of 3: 1 (v/w). The Precellys-24 homogenizer (Peqlab Biotechnologie GmbH) uses a figure-ofeight motion to rapidly gyrate beads to grind up to 24 samples, temperature-controlled (0-4 ° C), all at once with the following program: 3 cycles of 30 s at a frequency of 5,800 rpm with a 25-second pause between cycles. Homogenates and plasma samples were centrifuged at 18,000 g at 2 ° C for 5 min; the resulting supernatant (1.5 mL) was pipetted into a cryovial (Biozym GmbH, Oldendorf, Germany) and analyzed immediately to avoid degradation of the analytes.
Analytical Procedures
A flow injection analysis/mass spectrometry (FIA-MS)-based platform was employed for the simultaneous quantification of a broad range of endogenous intermediates, namely, acylcarnitines, amino acids, sphingomyelins, and glycerophospholipids. A liquid chromatography MS step was applied for the additional quantification of series of amino acids and biogenic amines, small organic acids, and the other members of the energy metabolism pathway, oxysterols and eicosanoids. Analytical protocols can be found in Urban et al. [36] and are validated according to the FDA bioanalytical method validation recommendation for industry [37] . Samples were randomized within and across the 2 analytical batches. All procedures before and after the analysis were performed by analysts blinded to the experimental groups. In total, 215 unique compounds were quantified. Analytes that did not meet the quality control criteria or were not detected in approximately 70% of the samples were not selected for further analysis, resulting in 182 unique metabolites being retained for analysis and reporting. The compounds OH-kynurenine, PEA, Nitro-Tyr, dopamine, OH-Pro were excluded from the plasma analysis, and OH-kynurine, NitroTyr, OH-Pro, 9-HODE, 12(15)-EpETE, 15S-HpETE, 5S-HpETE, LTD4, 8-iso PGF2, PEP, α-KGA, Tetr-P, 22ROHC, 20aOHC, 22SOHC, THC, 7aOHC, desmosterol, 7DHC, cholesterone, and 24DHLan were excluded from the brain analysis. A quantitative (or semiquantitative) targeted approach was employed, resulting in the generation of a normalized concentration value for the specific compound. Data preprocessing is therefore limited to 2 activities: the imputation of zero values and data transformation. A detailed list of all metabolites considered for interpretation is given in online supplementary table 1 (for all online suppl. material, see www.karger.com/doi/10.1159/000464131). In short, it comprised 25 acylcarnitines, 93 lipid derivatives (11 sphingomyelins, 72 glycerophosphatidylcholines, and 10 lysophospholipids), 21 amino acids, 11 biogenic amines, 12 eicosanoids and prostaglandins, 13 oxidized products of cholesterol (oxysterols), and 6 members of the energy metabolism pathway. Where the limit of detection was not reached for a given variable, then the value was set to zero and columns or rows comprising only zeros were removed prior to analysis. Data were formatted as a data matrix comprising 80 lines (samples) and 147 columns (metabolic variables).
Multivariate Statistical Analysis
Data were paretoscaled before analysis. Unsupervised principal-component analysis was run in both subpopulations to check sample homogeneity and exclude outliers. An O-PLS analysis (orthogonal projections to latent structures) [38, 39] was carried out to investigate the information shared by the mass-spectral matrix X and the descriptive-variable matrix Y. Spectra are visualized in scores plots and the metabolic variations sustaining the discrimination are presented in loadings plots. The O-PLS analysis was run to discriminate populations by regressing a supplementary-data matrix Y, containing information about the membership of samples to each group. Model performances were assessed by the goodness-of-fit parameters R 2 and Q 2 , related, respectively, to the explained and predicted variance. We performed model validation by resampling the model 1,000 times under the null hypothesis (i.e., by random permutation). Observed and predicted Y matrices were computed using an O-PLS-DA MATLAB routine developed in the lab. Receiver-operating characteristic (ROC) curves were plotted using MATLAB. These represent the true-positive rate as a function of the false-positive rate, and determine the best threshold for a given test to define the membership of a class. The diagonal stands for random prediction, whereas the more the curve moves to the top left corner, the better the prediction ability of the model is. Scaled-to-maximum, aligned and reduced trajectories (SMART) analysis [40] was used to cancel out the differences between the metabolic starting positions of the different groups and evaluate the metabolic trajectories with respect to time. O-PLS-VIP (variable influence on projection) allows the identification of variables that are important in the multivariate signature discriminating the 2 groups. O-PLS-VIPs were computed with a MAT-LAB routine based on the published algorithm [41] . VIP values >2 were chosen as variables of interest.
Results
Our first analysis evaluated if metabolic phenotyping could discriminate between samples from brain tissues from mice injected with PBS (controls) and the samples of brain injected with ibotonate (model of a focal lesion induced via excitotoxicity). Subsequent to this, as a post hoc analysis, we investigated the metabolic changes occurring between the different time points, in order to monitor the metabolic evolution induced by the excitotoxic lesion.
Between-Group Discrimination Analysis
Brain and plasma samples were analyzed with the aim of identifying metabolic differences between PBS-injected (control) animals and ibotenate-injected (lesioned) animals, and 7-10 samples were generated for each data point. Plasma samples did not exhibit significant metabolic variations. However, the PBS-and ibotenate-injected brain samples could be robustly separated via a computed single predictive component from the 1 + 7 component O-PLS analysis ( Fig. 1 a) . This is a dimension reduction technique that allows regression analysis where we know that some of our independent variables (metabolites) can co-vary. Goodness-of-fit parameters of the model were high, with an explanation capacity R 2 of 0.830 and a prediction capacity Q 2 of 0.677 (maximum = 1). We used 2 strategies to test the strength of our model to explain the difference between the control and ibotenate groups in this study, which was exploratory for the utility of metabolic phenotyping to discriminate these 2 groups. First, we used resampling under the null hypothesis. We identified, in comparison to our real data, that there was a clear decrease in the goodness-of-fit parameters ( Fig. 1 b) when the model is based on a random-class information matrix (decrease in R 2 and Q 2 with the correlation between the original and permuted sample identifications). An empirical p value was computed to measure the number of random models outperforming our initial real-data model. The p value was 0, demonstrating that no random model achieved better quality coefficients than the original real-data model, thus validating its robustness. Secondly, discrimination capacity was assessed using a cross-validated ROC ( Fig. 1 c) , showing an area under the curve (AUC) of 0.98, and further validating the strength of this model to explain the difference between the control and ibotenate groups.
To identify statistically significant variations of a single metabolite that would explain the observed difference, we used a univariate statistical analysis (analysis of variance) coupled with multiple-hypotheses testing correction (Benjamini-Yekutieli correction). This failed to identify a single discriminatory metabolite. Instead, we implemented O-PLS-VIP to identify, in a multivariate way, the metabolic changes that were important to explain the difference between the groups. VIPs were only derived from the predictive component of the model. Variables exhibiting a stringent O-PLS-VIP (>2 [41] ) were kept ( Fig. 1 d) . We observed an increase of many amino acids (glutamine, proline, serine, threonine, tryptophan, and valine) and the sphingolipid SM C26: 1 (sphyingomyelin, 26 carbon residues, 1 double bond) associated with the ibotenate lesion group compared with the PBS group, and a decrease in glycerophospholipids, i.e., the arachidonic acid-containing phosphatidylcholine (PC aa) 30: 2 and the PC aa C32: 3.
Time-Series Analysis
To evaluate the metabolic changes associated with time after the injection of either PBS or ibotenate within the 2 groups, we ran a time-series analysis. SMART analysis was performed ( Fig. 2 a) , showing 2 different metabolic trajectories (after PBS or ibotenate injection) across our time points (1, 2, 3, 5, and 25 days after the injury). Note that the 2 trajectories do not have the same starting point because we did not have a sample from a time point of zero (i.e., preinjury) in the analysis and the first samples were collected after exposure. The SMART analysis produced a first component that was associated with 69% of the explained variance and a second component associated with 21% of variance. It dropped below 5% for the third principal component. The metabolites and their direction of change collectively responsible for the variance within the 1st and 2nd principal components were identified ( Fig. 2 b) ; the values for each metabolite at each time point are presented in Figure 3 . It is worth noting that the model captured both the direction and magnitude of change, and, as such, a metabolite moving in opposing directions over time or due to treatment can appear in 2 principal components.
We considered how data change with respect to time within the PBS and ibotenate groups. Initially, the PBS and ibotenate samples had different positions along the 1st component but similar positions along the 2nd component. Across time points, the 2 metabolic trajectories had similar shapes (moving right to left within PC1 and top to bottom within PC2). However, the PBS trajectory had a greater range in the metabolic space for both PC1 and PC2. After 25 days, the 2 groups had close positions along the 1st component but clearly different positions along the 2nd component. Furthermore, the final position of the ibotenate signal along the 2nd component was equivalent to its initial position. It thus seems that the injury effects are translated in the metabolic space along the 1st component (variations in acylcarnitine, arginine, glutamine, phenylalanine, proline, serine, tyrosine, valine, glycerophospholipids, and sphingolipids), but that this difference was corrected after 25 days of development. However, in the PBS-only group, another metabolic difference appears (variations in arginine, glutamine, valine, and glycerophospholipids), showing a clear change over time in the 2nd component. This component was associated with an upregulation of arginine, glutamine, and glycerophospholipids, and a downregulation in valine. In this study, an MS-based metabolic phenotyping strategy was applied to evaluate the impact over time of an excitotoxic lesion in the developing mouse brain. We used O-PLS-based analysis to distinguish between the 2 groups at the 5 time points (1 + 7 components, R 2 = 0.830, Q 2 = 0.677). From this analysis, we observed that changes in concentrations of the amino acid and lipid biochemical classes were associated with the ibotenate injury. We also performed a time-series analysis (SMART), generating a model in which the first 2 principal components accounted for 90% of the data variance (69 and 21%, respectively). Investigating time-dependent changes was not the primary goal of this study. However, it can be noted that early time points were more associated with changes in the 1st component (including serine and sphingolipid SM C26: 1), and that later (tertiary) time points were more associated with changes in the 2nd component (including the glycerophospholipids, e.g., PC aa 36: 3).
In comparison to nuclear magnetic resonance (NMR) spectroscopy, MS-based strategies are justified for several reasons. The small amount of immature and/or specific brain regions in rodent models typically requires sample pooling for analysis via NMR. However, MS can be performed on individual animal samples, maintaining an optimal balance between statistical power and the number of experimental animals. In combination with the improved metabolite discrimination, the modularity of MS-based platforms allows a wider coverage of not only the metabolome but also of the specific class of metabolites by including those members present at a lower concentration. In the scope of this study, our targeted MS-based metabolic phenotyping enabled the simultaneous coverage of pathways that were hypothesized to represent intermediary metabolism involved in excitotoxic injury [42] , namely phospholipids, sphingomyelins, eicosanoids, oxidized products of cholesterol, acylcarnitines, and several members of the TCA cycle. In addition, the whole range of amino acids and several biogenic amines (e.g., serotonin and dopamine) central to brain research were also included.
Our O-PLS analysis comparing control and excitotoxic lesion metabolites produced a robust model that we validated to explain the vast majority of variance in the data. A limitation of the model validation is that we did not have access to an independent data set. The advantage of the O-PLS analysis is its supervised nature, allowing a focus on the specific effects of the study. However, the model displays information along predictive and orthogonal axes that should both be investigated. Although we were not able to identify a single metabolite responsible for a significant amount of variation in this model, we did identify a fingerprint of 9 metabolites belonging to the amino acid, glycerophospholipid, and sphingolipid families. It is, of course, likely that changes in these key factors are due to metabolic and cellular dysfunction including changes in the cellular composition of the injured brain.
Regarding the cellular composition of the brain and how this corresponds to the metabolic results, we previously characterized this model at 4 and 8 h, and 1, 2, 3, 5, and 20 days after inducing the lesion [2, 28, 43] . We observed that neuronal death occurs at 12 h after ibotenate injection, and becomes maximal at 24 h, but that there is no more neuronal loss by 48 h. Microglia increase substantially in number between 2 and 4 h, and their numbers remain elevated at 5 days. Regarding astrocytes, we observe that there is an initial reduction in number to a nadir at 24 h, and that numbers were greater than in the control by 48 h, and normalized between 5 and 25 days. We previously demonstrated that the microglia are the chief mediators of injury in this model, using pharmacological and antibody-mediated approaches [43] . Regarding the role of altered amino acids as revealed by our current analysis, microglial activation dynamics have been studied in depth with metabolomics approaches and these revealed specialized expression patterns of amino acids tied to activation states [44] . However, no specific associations could be made with amino acid changes in our data, given the heterogeneity in the cell types in this lesion. We can, nevertheless, mention that high levels of branch-chain animal acids such as valine favor astrocytedependent neurotoxicity by NMDA receptor activation and influence the gene expression and immune properties of microglial cells [45] . In addition, the increases in glutamine could be associated with the higher numbers of astrocytes within the lesion, as this amino acid is enriched in these glial cells [46] . Regarding the lipid class metabolites, the membranes of neural cells are composed of glycerophospholipids, sphingolipids, and assorted proteins asymmetrically distributed between the 2 lipid bilayers. Glycerophospholipids consist of 4 primary phospholipids; PC, phosphatidylethanolamine, phosphatidylserine, and phosphatidylinositol. Glycerophospholipids and sphingolipids play a role in the structural integrity of these neural membranes. Also, neuronal membrane phospholipids are important reservoirs for second messengers, such as prostaglandins, eicosanoids, platelet-activating factor and diacylglycerol. As such, we could suppose that there is a plausible link between increases in glial cell numbers and neuronal death profiles and the observations of metabolites. Supporting a facet of this, a recent study reports that the PC aa metabolites are enriched in the microglia, specifically in the spinal cord microglia after peripheral nerve injury [47] . In addition, the death of oligodendrocytes and the formation of a white-matter cyst is a key component of this model [35] . As such, it is logical that there were changes in sphingolipids, as sphingolipids are found in animal cell membranes, especially in the membranous myelin sheath which surrounds some nerve cell axons.
There are also previous reports on the effects of excitotoxicity on brain metabolites. Specifically, He et al. [48] identified variations in ceramide metabolism in a rat model of hippocampal injury induced by a excitotoxic lesion using kainate acid. We observed variations in amino acid (particularly serine) and sphingolipid metabolism that can be connected to ceramide metabolism. However, in our analysis, changes in these metabolites did not reach the level of statistical significance.
Using the SMART analysis to assess the metabolic trajectories over time, at the first time point (24 h), we noted there was considerable difference in the 1st component metabolites (such as C9 acylcarnitine and the sphingolipid SM C26: 1). We speculate that this variance was due to the significant excitotoxicity-induced changes in the brain tissue at this time point, namely cell death and gliosis [28] . Also, at the last time point, 25 days after the lesion (in the tertiary phase), it was previously observed in this model that gliosis has subsided but that a considerable lesion in the periventricular white matter remains. At this tertiary time point, the greatest variation identified by the SMART analysis was due to increases in metabolites from the 2nd component, such as the glycerophospholipids (PC aa 36: 3). Disturbance of the normal developmental processes are considered a major contributor to brain damage observed in preterm born infants, i.e., the encephalopathy of prematurity [49] . We speculate that this change in PC2 represents a developmental disturbance caused by the excitotoxic lesion. Although the study of normal development was outside the planned scope of this study, it is of interest to speculate that the PC2-related changes in the PBS (control) group likely reflected normal changes in cellular composition and cellular maturation.
Metabolic phenotyping has been shown to be useful in human cohorts in discriminating between variables as diverse as aging and viral infection [27] . Fluid-based metabolomics is an increasingly popular area of research in perinatal medicine, with studies related to neonatal encephalopathy and chorioamnionitis [26, [50] [51] [52] . Attempts have even been made to correlate metabolic changes with neuropathology in a sheep model of inflammation-driven perinatal brain injury [53] . This sheep study also demonstrated changes in the mid-term caused by injury, up to 10 days after insult, although this injury was more severe and likely to have also persisted into the tertiary phase, as in our study. We did not observe the multitude of changes in the metabolic phenotypes as observed in the sheep study. This is likely due to the more moderate nature of our injury, which also explains the limited effects we observed.
Analysis of injury in this model revealed that, at least by 24 h, there is a compartmentalization of response to injury in this model (no plasma changes). We can assume that there was little systemic-central crosstalk, as cell death and gliosis peaked at ≥ 48 h in this model, and, as such, that the metabolic changes were driven primarily by the events within the brain. This is an interesting facet of the model and will allow us to further refine brain-specific metabolic phenotypes for biomarker discovery.
In conclusion, this is the first assessment of the metabolic phenotype in a model of perinatal excitotoxicity, and it includes an analysis of the effects into young adulthood. We found that a shortlist of amino acids and glycerophospholipids explained the effects of the excitotoxic lesion. Furthermore, we found that there were differences in the normal processes of development, which could be visualized with this approach. These targets may be useful starting points for studies on acute-or tertiary-phase biomarkers specific to excitotoxic processes.
